Intrepid Financial Planning Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Intrepid Financial Planning Group’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,500	Closed	-$10.5K	–	136
2026 Q1	$10.5K	Hold	10,500	–	–	﹤0.01%	124
2025 Q4	$14.3K	Sell	10,500 -2,000	-16%	-$2.92K	0.01%	121
2025 Q3	$20K	Hold	12,500	–	–	0.01%	128
2025 Q2	$17.5K	Sell	12,500 -2,000	-14%	-$2.99K	0.01%	122
2025 Q1	$23.3K	Buy	14,500 +500	+4%	+$635	0.01%	117
2024 Q4	$17.6K	Sell	14,000 -5,000	-26%	-$7.76K	0.01%	121
2024 Q3	$35.7K	Sell	19,000 -1,000	-5%	-$3.95K	0.02%	125
2024 Q2	$148K	Buy	20,000 +4,000	+25%	+$32.9K	0.06%	118
2024 Q1	$125K	Hold	16,000	–	–	0.05%	119
2023 Q4	$81.3K	Sell	16,000 -2,000	-11%	-$10.3K	0.04%	117
2023 Q3	$107K	Hold	18,000	–	–	0.06%	112
2023 Q2	$134K	Sell	18,000 -1,000	-5%	-$8.51K	0.06%	113
2023 Q1	$180K	Sell	19,000 -1,000	-5%	-$10.6K	0.09%	109
2022 Q4	$213K	Hold	20,000	–	–	0.12%	96
2022 Q3	$148K	Hold	20,000	–	–	0.08%	96
2022 Q2	$96K	Buy	+20,000	New	+$114K	0.05%	103

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Compass Financial Management Tampa, Florida $829M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Intrepid Financial Planning Group's ATNM Position: Q2 2026 in Review

Intrepid Financial Planning Group sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 10,500 shares — an estimated $10.5K sold.

Intrepid Financial Planning Group first reported a position in ATNM in Q2 2022 and held it in 16 quarters. The position peaked at $213K in Q4 2022. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

Intrepid Financial Planning Group reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Intrepid Financial Planning Group sold 10,500 Actinium Pharmaceuticals shares in Q2 2026, an estimated $10.5K.
Intrepid Financial Planning Group first reported a position in Actinium Pharmaceuticals in Q2 2022 and held it in 16 quarters.
Intrepid Financial Planning Group's Actinium Pharmaceuticals position peaked at $213K in Q4 2022.
47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Intrepid Financial Planning Group's 13F filing for Q2 2026, filed 12 Aug 2026.